铽-161 SPECT/CT 定量成像:基于图像的剂量学可行性及陷阱
本研究通过体模测量评估铽-161(161Tb)SPECT/CT 定量剂量学的可行性,比较三种准直器与两个能量窗。结果显示 MEGP 准直器、75 keV 窗及均匀圆柱体校准因子定量准确性更优,低能准直器存在明显 septal penetration 并导致高活度水平系统性低估。
要点
- MEGP 准直器联合 75 keV 窗定量准确性优于 LEHR 和 ELEGP,差异有统计学意义(p ≤ 0.001)。
- 低能准直器观察到明显 septal penetration(如 292 和 475 keV)及高活度水平系统性低估。
- 75 keV 窗较 49 keV 窗提供更好的空间分辨率和对比度,49 keV 窗在高灵敏度下可能适用于晚期成像。
核心结论
- 基于 SPECT/CT 的高精度 161Tb 定量是可行的,支持 161Tb 作为诊疗一体化替代核素。
- MEGP 准直器、75 keV 窗及均匀圆柱体测量的校准因子为优选方案。
研究设计与样本
- 采用 GE Discovery NM/CT 670 Pro 系统进行系列体模测量,评估三种准直器(ELEGP、LEHR、MEGP)和两个能量窗(75 keV γ 峰 ±10%;49 keV γ 峰及附近 X 射线 40.7-62.9 keV)。
- 使用临床 OSEM 重建算法,并纳入含 8 个球形插件的 LungSpine 体模及 3 种不同本底活度水平。
主要发现
- ELEGP 的 SPECT 校准因子平均比 MEGP 和 LEHR 高 2 倍,49 keV 窗比 75 keV 窗高 3 倍。
- 各准直器的校准因子随测量和感兴趣体积几何形状显著变化,49 keV 窗较 75 keV 窗更明显。
- 两个 3D 打印肾脏插件测量中 LEHR 的视觉图像质量优于 ELEGP 和 MEGP。
- 所有准直器下 75 keV 窗的空间分辨率和对比度均优于 49 keV 窗。
- LungSpine 体模研究中 MEGP 的定量准确性优于 LEHR 和 ELEGP,两个能量窗均具统计学显著性(p ≤ 0.001),49 keV 窗误差通常大于 75 keV 窗。
关键数值与推荐
- 推荐 MEGP 准直器、75 keV 能量窗及基于均匀圆柱体测量衍生的校准因子用于 161Tb SPECT/CT 定量。
- 49 keV 窗因高灵敏度可能适用于晚期成像时间点,但需进一步优化。
临床怎么用
- 临床开展 161Tb SPECT/CT 剂量学时优先选用 MEGP 准直器和 75 keV 窗,并以均匀圆柱体校准因子进行定量。
- 低能准直器因 septal penetration 和高活度水平系统性低估,不推荐用于高精度定量。
局限性
- 低能准直器存在穿透及后续下散射导致的退化,可能需更精细重建来缓解。
- 鼓励进一步研究死时间效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Terbium-161 (161Tb) is a promising β⁻-emitter for theragnostics. However, its complex photon emission pattern-including intense X-rays and low-yield, high-energy γ-emissions-may complicate image-based quantification. This study aimed to assess the feasibility of accurate SPECT/CT-based 161Tb dosimetry through a series of phantom measurements using a GE Discovery NM/CT 670 Pro system. Three collimators were evaluated: extended low-energy general-purpose (ELEGP), low-energy high-resolution (LEHR), and medium-energy general-purpose (MEGP), using two separate energy windows: around the 75 keV γ-peak (± 10%), and around the 49 keV γ-peak and nearby X-rays (40.7-62.9 keV). A clinical OSEM reconstruction algorithm was employed. RESULTS: On average, the SPECT calibration factors (CFs) were 2-fold higher with ELEGP compared to MEGP and LEHR, and 3-fold higher at 49 keV compared to 75 keV. For each collimator, derived CFs varied substantially depending on measurement and volume-of-interest geometry-more so at 49 keV, compared to 75 keV. Measurements of two 3D-printed kidney inserts revealed superior visual image quality with LEHR compared to ELEGP and MEGP. Across all collimators, the 75 keV window provided better spatial resolution and contrast than the 49 keV window. An anthropomorphic phantom study, including a LungSpine phantom with 8 spherical inserts and 3 different background activity levels, demonstrated a greater quantitative accuracy for MEGP compared to LEHR and ELEGP, with statistical significance for both energy windows (p ≤ 0.001). Errors were generally larger at 49 keV compared to 75 keV. For the low-energy collimators, considerable septal penetration (e.g., at 292 and 475 keV) was observed, along with systematic underestimation at high activity levels. CONCLUSIONS: This study demonstrates that highly accurate SPECT/CT-based 161Tb quantification is feasible, further cementing 161Tb as a viable theragnostic alternative. A MEGP collimator, a 75 keV window, and a CF derived from a homogeneous cylinder measurement appears preferable. The 49 keV window could be useful at late imaging time points, given its high sensitivity, if further optimized. Degradation from penetration and subsequent downscatter may be mitigated with a more refined reconstruction. Further investigations into dead-time effects are encouraged.
引用
- Westerbergh F, van der Meulen NP, Müller C, et al. Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls. EJNMMI Res. 2025. PMID: 41082018. doi:10.1186/s13550-025-01326-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。